Aldeyra Therapeutics Hosts Webcast and Conference Call to Present Full Year 2021 Financial Results and Discuss Recent Corporate Highlights

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET on Thursday, March 17, 2022 to present its financial results for the fiscal year ended December 31, 2021 and discuss recent highlights of the company.

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 132077. A live webcast of the conference call will also be available on the Investors and Media page of Aldeyra’s website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immune systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokines, systemic mediators of inflammation known as RASPs (reactive aldehyde species). Reproxalap is undergoing phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in phase 2 proof-of-concept clinical trials in psoriasis, asthma and COVID-19. Our pipeline also includes ADX-2191 (0.8% intravitreal methotrexate), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook and Twitter.

Michael P. Boser